Logo
Donate
  • COVID-19
    • Contract Research Opportunities
    • COVID-19 Research Timeline
    • COVID-19 News
    • Supporting our Community
    • COVID-19 vaccine trials
  • Friends of VIDO
    • Donor Roll
    • Donor News
    • Why Donate?
  • About
    • History
    • Mission, Vision, Values
    • Safety & Security
    • Community Liaison Committee
    • Annual Reports
    • Contact
  • Team
    • Board of Directors
    • Senior Leadership
    • Science Management
    • Principal Scientists and Veterinarians
    • Scientific Advisory Board
    • Access Committee
  • Research
    • Contract Research
    • Clinical Research & Animal Care
    • Patents
    • Publications
  • Facilities
    • Vaccine Development Centre
    • Accessing InterVac
    • Specialized Equipment and Facilities
  • Careers
    • Current Opportunities
    • Training
    • Visiting Scientists
    • Living in Saskatoon
    • VIDO Post Doctoral Association
  • News
    • VIDO’s first Animal Health Summit brings animal health stakeholders together to prepare for foot and mouth disease
    • VIDO led technology a key part of the vaccine protecting koalas from chlamydia
    • VIDO scientists strengthen mpox preparedness
    • VIDO and Pirbright expand collaboration to advance vaccine manufacturing
    • USask’s VIDO selected for CEPI’s international research network
    • VIDO receives significant CIHR support for research into emerging coronaviruses
    • VIDO awarded U.S. contract for its Vaccine Development Centre
    • CEPI awards USask’s VIDO $6M for vaccine development
    • New funding will help predict SARS-CoV-2 variants and protect vulnerable populations
    • Saskatoon hospital foundations offer support to USask’s VIDO
    • New VIDO Vaccine Development Centre supports vaccine innovation protecting Canadians, animals
    • New support for VIDO as a research facility of national importance
    • New $8.1 million funding for VIDO will protect Canadians and our animals from high consequence pathogens
    • VIDO’s economic impact over half a billion dollars: SREDA study
    • VIDO first non-U.S. organization invited to join high containment network
    • CIHR supports research targeting high impact infectious diseases
    • Integrating field and laboratory studies to better predict the next emerging zoonotic pathogen
    • The avian influenza outbreak: what you need to know
    • VIDO partners with four research hubs to strengthen Canada’s infectious disease preparedness
    • VIDO scientists receive leadership awards for excellence in vaccine research
    • VIDO and VFI collaborate to strengthen pandemic preparedness
    • Saskatchewan Blue Cross invests $150K to help establish USask’s VIDO as Canada’s Centre for Pandemic Research
    • VIDO awarded over a million dollars for innovative research projects
    • USask’s VIDO announces positive Phase 1 results for COVAC-2
    • VIDO research provides insight into the immune response and possible long-term health impacts associated with COVID-19
    • Infectious disease research bolstered by Hospitals of Regina Foundation
    • Saskatoon couple donates $1 million to VIDO to enhance ground-breaking vaccine research
    • AnGes Collaborates with University of Saskatchewan’s VIDO-InterVac to Develop Ebola Polyclonal Antibody Therapy Using DNA Vaccine Technology
    • Canadian universities partner to fight COVID-19 at USask’s VIDO-InterVac
    • Director Andrew Potter's Blog: Why skipping the flu shot is a selfish gamble
    • Investments in USask livestock research fuels innovation, protects animal health
    • Developing oral vaccine for chronic wasting disease goal of funding research
    • A new opportunity to develop livestock and human vaccine in Saskatchewan: SARM supports VIDO‘s effort to strengthen the response to infectious disease
    • USask hosts the Prime Minister of Canada
    • VIDO: Advancing human, animal health at home and abroad
    • VIDO: Saskatchewan’s gift to global health
    • CEPI: The Race to Future-Proof Coronavirus Vaccines
    • Researchers’ study of Salmonella transmission first of its kind
    • New funding to advance Canada’s beef sector
    • Individual donors vital for VIDO to become Canada’s Centre for Pandemic Research
    • VIDO part of western Canadian team developing tools to stop chronic wasting disease
    • Research team aims to develop vaccines for prion diseases
    • Canada needs to plan for inevitable future pandemics
    • Leaders in discovery: five USask researchers honoured with top provincial health awards
    • USask researchers seek to prevent liver disease, high blood pressure, and understand lifelong impacts of Zika virus
    • Sask.-based research offers hope in unsettling times
    • Three USask researchers become fellows in the Canadian Academy of Health Sciences
    • Prime Minister announces new support for COVID-19 medical research and vaccine development
    • USask VIDO-InterVac awarded $23M for COVID-19 vaccine research
    • ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19
    • A first hand ebola experience
    • Ebola concern on the rise for Canadians
    • Worry more about getting flu shot, not Ebola: VIDO
    • VIDO-InterVac 2013-2014 Annual Report released
    • Canada and China expand collaboration in health education and research
    • Researcher hunts for faster gonorrhea test
    • VIDO-InterVac Director featured on Canada Am
    • VIDO-InterVac attains ISO 9001:2008 certification
    • VIDO-InterVac PhD student wins best poster award
    • VIDO celebrates certification of the International Vaccine Centre at the University of Saskatchewan
    • PREVENT and VIDO sign collaborative agreement with South China United Vaccine Institute and Guangzho Institute of Respiratory Disease
    • VIDO-InterVac scientists receive $1M in Agricuture Funding
    • Former VIDO Director Lorne Babiuk inducted into Saskatchewan Agriculture Hall of Fame
    • Young Innovators - Researcher hunts for hepatitis C cure
    • VIDO-InterVac researchers address cattle disease and food security in Kenya
    • VIDO-InterVac Director interviewed by MacLeans: Fighting scary vaccine stories with scarier no-vaccine stories
    • Biotechnology Focus: InterVac - New opportunities in infectious disease research
    • Former VIDO-InterVac Director Dr. Lorne Babiuk honored with Gairdner Wightman Award
    • VIDO-InterVac scientists receive funding from Canadian Swine Health Board
    • VIDO-InterVac researcher receives CIHR Operating Grant
    • U of S VIDO-InterVac Joins National Launch of Canada’s new $100 bank note
    • U of S International Vaccine Centre Celebrates Grand Opening
    • VIDO-InterVac: Leading Vaccine Discovery
    • Andrew Potter Blog: Vaccine challenges and opportunities
    • VIDO-InterVac: Keeping Canada at forefront of discovery science
    • VIDO-InterVac Board Chair wins prestigious award
    • BIOTECanada Insights Feature: InterVac
    • Researchs at U of S VIDO-InterVac close in on vaccine to protect babies
    • U of S alumnus and tech helping in fight against Ebola
    • VIDO-InterVac at the U of S hosts international experts in human, animal health
    • VIDO-InterVac announces new Associate Director, Operations and Maintenance
    • VIDO-InterVac signs exclusive license agreement for developing a novel vaccine against Respiratory Syncytial Virus
    • VIDO-InterVac at U of S signs exclusive license agreement for developing a vaccine against Chronic Wasting Disease
    • The VIDO Swine Technical Group discusses swine production
    • VIDO-InterVac Scientist named new Jarislowsky Chair in Biotechnology
    • Publication: VIDO Beef Technical Group and Dr. Steven Hendrick
    • U of S student develops new E. coli vaccine
    • VIDO-InterVac Scientist Named New Canada Research Chair
    • VIDO-InterVac Major Partner in HIV/AIDS Vaccine Pilot Plant Bid
    • U of S VIDO Scientist develop revolutionary new research tool
    • Associate Director Paul Hodgson's Biotech Blog: An ounce of prevention
    • World's first cattle vaccine to reduce E. coli O157:H7 threat receives full licensing approval in Canada
    • More funds for infectious disease research, vaccine development
    • Saskatchewan delegation to attend biotech conference
    • VIDO launches $2-million project with India to develop tools for improved food safety
    • VIDO team awarded $445,000 from PrioNet Canada for BSE vaccine
    • VIDO scientist receives $620,000 to tackle respiratory disease
    • Pan-Provincial Vaccine Enterprise (PREVENT) announces board members, vaccine targets
    • VIDO awarded $2.4 million for vaccine coverage tailored to Saskatchewan's needs
    • VIDO scientist receives university teaching excellence award
    • VIDO key stakeholder in Centre of Excellence for Commercialization and Research
    • InterVac weathers market pressure and wins final approval
    • Sod-Turning Celebration Launches U of S International Vaccine Centre
    • New Associate Director of Research Named
    • Saskatoon is building success in vaccine research
    • New VIDO Director Named
    • Community Liaison Committee Launched for U of S InterVac
    • Colorado State University to confer honorary degree on VIDO director
    • Government of Saskatchewan commits $24.7 million to InterVac
    • VIDO Director accepts new position at University of Alberta
    • Groundbreaking vaccine co-developed by U of S VIDO approved to protect water and food supply from E.coli O157:H7 contamination
    • Bioniche E. coli O157:H7 Cattle Vaccine Authorized for Field Use in Canada
    • U of S VIDO team discovers key step in flu virus replication
    • International Centre for Infectious Diseases Names New Board Chair
    • Maternal Immunization May Protect Newborns from Whooping Cough U of S VIDO Study
    • Lorne Babiuk invested into Order of Canada
    • Dr. Paul Hodgson joins VIDO as Associate Director of Business Development
    • U of S Researchers Develop New Vaccine Candidate Against Hepatitis C
    • Lorne Babiuk receives SHRF Achievement Award (Biomedical Research)
    • VIDO Director named Officer of the Order of Canada
    • New $24 million InterVac funding to benefit Canadian livestock industry
    • City of Saskatoon Invests $250,000 in International Vaccine Centre
    • VIDO Awarded $4 M for Industrial Research Chairs in Food Safety
    • VIDO to headquarter $61.8 million International Vaccine Centre
    • VIDO Tech Report: VIDO-developed SARS vaccine candidates fast-tracked to testing
    • VIDO Tech Report: Horse knowledge helps researchers solve cross-species diseases
    • $19.2 Million Awarded to U of S to Help Build International Vaccine Centre
    • VIDO Tech Report: VIDO uses livestock expertise to tackle whooping cough in humans
    • U of S and Partners Celebrate Grand Opening of $17.8 M VIDO Expansion
    • VIDO director receives Saskatchewan Order of Merit
    • New vaccine technology offers multi-benefits for livestock producers
    • VIDO Director honoured for lifetime commitment to animal health
    • VIDO name updated to Vaccine and Infectious Disease Organization
    • Platform technologies power a new generation of vaccines
    • VIDO targets world's first vaccine for Hepatitis C
    • Researchers test pig virus protein to produce vaccine
    • Funding announced for vaccine against CWD
    • New IDRC funding backs VIDO-InterVac research to benefit cattle producers in Kenya
    • Should you be getting your measles vaccine?
    • Unique collaboration will combat deadly disease found in pigs
    • Meat system safe despite BSE case
    • Funding announced to enhance influenza vaccine research and development
    • Associate director receives honorary diploma
    • Funding awarded to develop vaccines for bovine tuberculosis and Johne’s disease
    • VIDO-InterVac celebrates its 40th Anniversary today with release of 2014-2015 Annual Report
    • Line Blurs Between Animal and Human Health
    • Dr. Philip Griebel receives 2015 AAVI Distinguished Veterinary Immunologist Award
    • Young Innovators: U of S student works on cattle vaccine for 'lung plague'
    • UofS Expert Weighs on Zika Virus Outbreaks
    • Recent H1N1 virus outbreak
    • Zika virus travel warning
    • VIDO-InterVac Director cautions winter vacationers on CBC radio
    • VIDO-InterVac Develops Vaccine for Devastating Pig Virus
    • VIDO-InterVac Research Fellow Jo-Anne Dillon named to Royal Society of Canada
    • Former VIDO-InterVac Director wins World Agriculture Prize
    • VIDO-InterVac receives funding from the Saskatoon Poppy Fund to support students researching Tuberculosis
    • VIDO-InterVac awarded $19.3 million to advance innovation
    • VIDO-InterVac helping to fight Zika virus
    • Tackling infectious diseases: Canada’s role in the global effort
    • VIDO-InterVac to field test a bovine TB prototype vaccine in 2 years
    • Going viral
    • VIDO-InterVac releases 2016-2017 Annual Report
    • The search continues for TB and JD vaccines
    • VIDO-InterVac tackles infectious diseases in world-class facilities
    • Dr. Andrew Potter receives SHRF Achievement Award
    • Saskatoon researcher Dr. Andrew Potter honoured with lifetime achievement award
    • 'A few infected people can really impact what goes on locally'
    • International Partnership Results in New Vaccine for Cattle in Africa
    • U of S gets major federal boost for isotope and vaccine production, water research
    • Federal investment helps bring vaccine manufacturing facility to Saskatoon
    • How a new vaccine could save cattle herds – and livelihoods
    • Six world-first vaccines among USask’s VIDO-InterVac contributions to global health
    • Volker Gerdts Named as New VIDO-InterVac Director and CEO
    • USask VIDO-InterVac expands international role to test antiviral compounds against COVID-19
    • Lung plague vaccine wins international award
    • Increasing Canada’s Preparedness for African swine fever with the University of Saskatchewan’s VIDO-InterVac
    • VIDO-InterVac approved to work on SARS-CoV-2
    • Extending the lifespan of N95 masks
    • New CT scanner gives USask’s VIDO-InterVac scientists a window on COVID-19 disease
    • VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval
    • A new year, and a new look
    • USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV
    • VIDO gains provincial support towards becoming a ‘Centre for Pandemic Research’
    • Canada’s Global Nexus and VIDO join forces to combat COVID–19
    • Federal budget supports USask’s VIDO with $59.2M
    • Young Innovators: U of S research team aims to develop salmonella vaccine
    • Young Innovators: Innovative research finds influenza detection system in body
    • Early research promising for new sheep respiratory vaccine
    • Agencies search for ASF vaccine
    • Using a new approach to create the first bovine tuberculosis vaccine
    • 2018 STIC Award winners showcased during third annual event
    • Vaccine development speeding up
    • New CFI funding will foster long-term sustainability of two USask national research facilities
    • Dr. Andrew Potter receives 2019 Saskatchewan Order of Merit
    • Efforts to Create ASF Vaccines Result in Cautious Optimism
    • Reverse vaccinology approach for novel bovine tuberculosis vaccines: The Canadian ReVAMP project
    • Dr. Andy Potter among Saskatchewan Order of Merit recipients
    • TB in bison studied at LFCE and VIDO-InterVac
    • Canada needs small-scale vaccine manufacturing to support research, and help save human and animal lives
    • Novel vaccination approach enhances worker safety
    • U of Sask. could help prepare for outbreaks by producing human vaccines for Canada, centre director says
    • USask’s VIDO-InterVac and South Korean’s International Vaccine Institute to undertake scientific exchanges
    • Mild Zika infection in fetuses may cause brain abnormalities
    • Saskatchewan Funds Coronavirus Vaccine Research
    • Canadian scientists first to test novel diagnostic tool for TB in bison
    • Saskatchewan government invests $3.6M in USask COVID-19 vaccine research
    • VIDO-InterVac-led research team at USask awarded almost $1M to fight new coronavirus
    • Canada’s plan to mobilize science to fight COVID-19
    • PM announces $12M for new vaccine manufacturing at USask’s VIDO-InterVac, part of $23.3M for the lab to fight COVID-19 and other infectious disease threats
    • New Money Aids Saskatchewan’s Search For Covid-19 Vaccine
    • USask VIDO-InterVac and International Vaccine Institute collaborate on COVID-19 work
    • SHA and VIDO-InterVac partner to help ensure supply of N95 respiratory masks
    • USask’s VIDO-InterVac and the National Research Council of Canada collaborate to advance development of vaccine against COVID-19
    • Promising pre-clinical results for USask VIDO-InterVac COVID-19 vaccine
    • CFI awards $77.5M to help major USask science facilities address COVID-19 and other global challenges
    • VIDO-InterVac on track to become ‘Canada’s centre for pandemic research’
    • USask livestock research receives significant investment to advance industry
    • New support to produce COVID-19 vaccines and treatments in Canada
    • Ministers Champagne, Joly and Carr highlight Budget 2021 biomanufacturing investments
    • Alumni Ron and Jane Graham’s $5.9M gift assists vaccine research, Huskie Athletics, engineering and education students at USask
    • The University of the Sunshine Coast leads rollout of critical vaccine for koalas